FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.
The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.